FDA-Approved Drug Manufacturing Deals Shift to Europe

Why It Matters

The trend weakens U.S. reshoring ambitions and cements Europe—especially Germany—as a primary manufacturing hub for American pharma demand.

Key Takeaways

• 2025 U.S. deals fell; Europe tripled U.S. volume.
• 15% tariff hasn't deterred European contract manufacturing.
• Germany secured 12 deals, leading European market.
• Novo Nordisk, Eli Lilly invest $3.5B in Europe.
• Diversified supply chains mitigate U.S. political risk.

Pulse Analysis

The post‑pandemic rebound has revived contract manufacturing activity, but the recovery is uneven. GlobalData reports that while U.S. deal volume hit a five‑year low in 2025, European contracts surged, outpacing domestic agreements by a factor of three. This divergence reflects more than temporary demand spikes; it signals a strategic pivot toward established European capabilities, especially in Germany, which captured 12 of the 14 U.S.‑focused deals. The 15% tariff imposed by the United States has proven insufficient to redirect biopharma sourcing back home, highlighting the limited leverage of trade barriers in a highly specialized industry.

Supply‑chain resilience has become a top priority for pharmaceutical executives amid geopolitical uncertainty. By diversifying production across the Atlantic, companies can hedge against sudden policy shifts, regulatory delays, or domestic capacity constraints. The move also aligns with broader industry trends favoring "just‑in‑time" manufacturing models that rely on reliable, high‑quality facilities. Europe’s mature regulatory environment, skilled workforce, and advanced infrastructure make it an attractive alternative to the fragmented U.S. contract manufacturing landscape, where capacity gaps and labor shortages persist.

Capital allocation decisions further reinforce the European tilt. Novo Nordisk’s $501 million expansion of its Irish tablet plant and Eli Lilly’s $3 billion investment in European sites illustrate confidence in the region’s ability to meet U.S. market demand, especially for high‑growth products like the oral GLP‑1 agonist Wegovy. These sizable commitments not only boost local employment but also create a feedback loop that strengthens Europe’s position as a pharma hub. For U.S. policymakers, the shift poses a challenge to reshoring agendas, suggesting that future incentives must address more than tariff relief, focusing on capacity building and regulatory alignment to remain competitive.